Masimo (MASI) shares soared 8.7% in the last trading session to close at $121.42. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.5% loss over the past four weeks.The sharp upsurge in Masimo's shares can be attributed to the surprising news regarding the company's newly elected Board of Directors. On Sept. 19, per a public statement issued from Politan, activist investor Quentin Koffey, and his Politan Capital Management group’ ...

Activist investor Politan Capital won the two board seats it was seeking at medical technology company Masimo, defeating founder and CEO Joe Kiani and another director, Chris Chavez, at the shareholder vote.Masimo shares rose more than 2% in extended trading. Politan nominees Darlene Solomon and Bill Jellison will join Politan investment chief Quentin Koffey and former Johnson & Johnson executive Michelle Brennan, who obtained board seats in a prior proxy fight last year."We look forward to meeting with, le ...

Masimo (MASI) recently announced that a U.S. court has found Politan Capital and its managing partner, Quentin Koffey, guilty of violating a sealing order by releasing information from ongoing court proceedings in a press release dated Sept. 12.This incident is likely to become a critical factor in the lead-up to Masimo’s 2024 Annual Meeting on Sept. 19, where Politan aims to replace several board members, potentially leading to the ousting of the company’s long-standing CEO and founder, Joe Kiani. The ruli ...

Masimo Corporation (MASI) , on Friday, announced a partnership with Google. The tie-up aims to develop a new reference platform for original equipment manufacturers (OEMs) building Wear OS by Google smartwatches.OEMs who adopt the new Masimo platform will continue to design and produce their new smartwatches’ physical exteriors. However, the devices’ interiors, including optimized hardware and software components, biosensors, and a companion Android smartphone app, will be provided by Masimo. This is expect ...

Masimo Corporation (MASI)  has announced a partnership with Qualcomm Technologies to create a next-generation smartwatch reference platform for Wear OS by Google.The collaboration is aimed at combining Masimo's expertise in advanced biosensing technologies with Qualcomm's Snapdragon wearable platforms. This reference platform is expected to help original equipment manufacturers (OEMs) develop high-performing smartwatches more efficiently, providing accurate health tracking and superior connectivity through ...

After tangling in court with Apple over smartwatch features, medical technology company Masimo is teaming with Google.The company announced in a news release Saturday (Sept. 14) that it was working with Google to develop a new reference platform for original equipment manufacturers (OEMs) building the tech giant’s Wear OS smartwatches. The platform, the company said, will allow OEMs to more efficiently bring Wear watches to market, incorporating Masimo’s biosensing technologies and standardizing smartwatch ...

For Immediate ReleaseChicago, IL – September 16, 2024 – Today, Zacks Equity Research discusses Intuitive Surgical (ISRG) , Masimo Corp. (MASI) and Veracyte, Inc. (VCYT) .Industry: Medical InstrumentsLink: https://www.zacks.com/commentary/2335903/3-medical-instruments-industry-stocks-to-buy-on-genai-and-ma-boostThe Medical Instruments industry is again in a transformative phase, thanks to the rapid adoption of generative Artificial Intelligence (genAI) and digital therapeutics, which market watchers expect w ...

Masimo Corporation (MASI) , on Monday, announced that France-based Saint-Denis Hospital Center will be adopting the use of its SafetyNet cloud-based telemonitoring platform as part of an experimental mobile neonatology unit aimed at facilitating earlier discharge of premature newborns from the ICU to the home. Launched in February, the project is expected to allow vulnerable neonates to return home safely while remaining under the close supervision of the hospital.Although the deal with Saint-Denis Hospital ...

文章核心观点 - 医疗技术公司Masimo正与激进投资者Politan进行代理权之争 [1][2][3] - Masimo CEO Joe Kiani向主要投资者RTW Investments透露了未公开信息 [1][3] - Politan指出Masimo业绩不佳,并推动公司剥离消费业务 [2] - Masimo与苹果公司就脉搏血氧测量技术存在诉讼 [3] - Kiani与美国总统拜登关系密切,其顾问之一曾担任拜登2020年竞选经理 [3] 根据相关目录分别进行总结 Masimo与Politan的代理权之争 - Politan正试图在本月的股东大会上替换Masimo两名董事,包括CEO Kiani [1][2] - Politan此前已在2023年获得两个董事会席位,包括管理合伙人Quentin Koffey [4] - Politan指责RTW存在"空头投票"行为,即支持管理层提名的董事候选人,但实际上已不再持有相应股票 [2] Kiani向RTW透露未公开信息 - Kiani在发布公告前12小时向RTW投资组合经理Yalamanchi透露了即将发布的公告内容 [1][3] - 这违反了SEC的Regulation FD规定,要求公司必须及时向所有人披露信息 [3] - Masimo方面表示知悉RTW正在积累大量持股,并支持Kiani的领导 [2] Masimo的业绩和战略 - Politan指出Masimo业绩不佳,并批评Kiani两年前进行的一项消费业务收购失败 [2] - Politan推动Masimo考虑将消费业务剥离 [2] - Masimo主要业务是生产用于监测人体血氧含量的医疗设备,并与苹果公司就相关技术存在诉讼 [3]

Earlier this month, Masimo subpoenaed proxy advisors ISS and Glass Lewis for their private communications with investors about the upcoming proxy contest with activist Politan Capital, according to people familiar with the matter.The unusual move comes after the medical device company delayed its annual meeting and sued Politan Capital in federal court earlier this summer. Masimo founder Joe Kiani, a close confidante of President Joe Biden, has framed the upcoming vote as existential.Glass Lewis disclosed t ...